SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix's upcoming earnings are sparking active debate, especially after the stock traded down in the after-hours session. While revenue was in line with estimates, EPS missed, and some community members are attributing the dip to a tax dispute in Brazil and broader concerns about content. A potential stock split and the impact of increased competition and advertising revenue are also key talking points.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending due to its acquisition of Railbird, a prediction market platform, sparking discussions about the company's expansion into new markets beyond sports betting. While some express excitement about this growth and potential, others are skeptical, citing concerns about profitability and regulatory challenges, with community members closely watching how this move impacts the stock's value.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending as the stock experiences a significant pullback, prompting community discussion about potential bottom levels and future catalysts. Despite the recent downturn, some investors express confidence in the company's long-term prospects, citing a major deal with Microsoft and overall growth in the AI sector. Community members are actively debating whether to buy the dip or wait for further price declines.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is trending due to anticipation surrounding its upcoming earnings report, with the community actively discussing potential outcomes and guidance. Bullish sentiment suggests the company will beat expectations, driven by strong global adoption of its da Vinci systems and procedure growth, despite concerns about tariffs and margin pressures. Traders are also closely monitoring unusual options activity and technical indicators for potential short-term opportunities.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending due to a proposed private offering of convertible senior notes, leading to community discussion about dilution and its impact on long-term holders; some view this as a strategic move to secure funding before positive catalysts, while others express concern about the company's financial management and potential for further offerings; the community is also debating the recent analyst downgrade and its effect on the stock's trajectory.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amidst speculation of a potential acquisition, with Paramount Skydance reportedly interested in making a bid, although the deal's likelihood is debated. Community chatter revolves around potential offer prices and whether WBD will accept, with some anticipating a bidding war involving other major players like Netflix or Comcast. The stock's movement reflects investor uncertainty surrounding these ongoing acquisition rumors and what price a deal could actually happen at.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments is trending following its latest earnings report, with revenue exceeding expectations but EPS falling slightly short, leading to mixed sentiment. The community is actively discussing whether the results justify the stock's valuation amidst broader concerns about the macro environment and potential tariff impacts. Some believe TXN is undervalued and poised for a rally, while others are wary of the company's guidance and competitive landscape.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Minerva Neurosciences Inc

Minerva Neurosciences ($NERV) is trending due to a massive surge following news of a $200M financing deal aimed at advancing its schizophrenia treatment. Community chatter revolves around the potential for significant gains, while some traders caution about a possible pump and dump, leading to high volatility. The funding is viewed as a strong indicator of confidence in the drug's approval, sparking debates about its long-term potential versus short-term trading opportunities.

rYojbaba Co., Ltd. engages in providing consulting and health services to improve and restore physical and mental health diminished by work-related stress. It operates through the Labor Consulting Services and Health Services segments. The Labor Consulting Services segment provides labor and corporate consulting services to foster constructive employment relationships between companies and employees. The Health Services segment provides health services through osteopathic clinics and osteopathic beauty salons to alleviate physical ailments primarily created by work related stress. The company was founded by Masataka Sakai on January 5, 2015 and is headquartered in Fukuoka, Japan.

rYojbaba Co. Ltd.

rYojbaba Co., Ltd. 

rYojbaba Co., Ltd. ($RYOJ) is trending due to a significant surge in price and volume, prompting discussions about potential short squeezes and comparisons to other recent high-momentum stocks. The community is actively speculating on targets and potential sympathy plays, with some noting the stock's low float and recent IPO status. News of partnerships may be contributing to market stimulation.

Sweetgreen, Inc. owns and operates a chain of salad restaurants. It offers drinks, sides, local bowls, salads, plates, and warm bowls. The company was founded by Nicolas Jammet, Jonathan Neman, and Nathaniel E. Ru in November 2006 and is headquartered in Los Angeles, CA.

Sweetgreen Inc - Ordinary Shares - Class A

Sweetgreen ($SG) is trending as chatter suggests a potential short squeeze ahead of earnings, with community members noting high put/call ratios and significant options activity. Some investors believe the stock is oversold and undervalued, especially given its robotics technology from the SPYCE acquisition, while others are eyeing it as a sympathy play with other heavily shorted stocks like BYND making moves. Community members are actively discussing the potential for a gamma squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Therma Bright, Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX), a burgeoning name in the medical device industry, has achieved a significant breakthrough for its flagship product, the Venowave VW5. This circulation-enhancing device recently secured a crucial designation from the Centers for Medicare and Medicaid Services (CMS), positioning it for success within the expansive Medicare and Medicaid frameworks.The Venowave VW5 has been awarded a permanent Healthcare Common Procedure Coding System (HCPCS) code, a pivotal development that could propel Therma Bright into the forefront of the deep vein thrombosis (DVT) treatment market. Industry estimates project this market to grow to $1.5 billion by 2032, offering substantial growth prospects for Therma Bright, which currently holds a modest market cap of USD $21 million.Introducing Therma Bright: Innovating Blood Clot Prevention, and BeyondTherma Bright, Inc., the innovative force behind the Venowave VW5, specializes in cutting-edge diagnostic and medical device technologies. While the company boasts a diverse portfolio, the Venowave VW5 is currently generating the most investor enthusiasm.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_14_31_PM_5254def16f.png" alt="Screenshot 2024-09-10 at 5.14.31 PM.png">The Venowave VW5 is a device designed to be worn on the calf, where it generates wave-like motions to massage the leg and promote blood circulation. This function is critical in pushing blood back to the heart, helping to prevent blood clotting, particularly in cases of DVT—a condition that affects approximately 900,000 Americans annually, according to the CDC. Unlike traditional compression socks, which can cause discomfort and skin issues, the VW5 offers a more comfortable and effective alternative for DVT patients.Venowave VW5 Achieves Key Medicare &amp; Medicaid DesignationThe Venowave VW5 is the first device of its kind to be classified as Durable Medical Equipment (DME) with a new HCPCS Level II code. This designation enhances the device's credibility as a treatment option and streamlines billing and reimbursement processes through Medicare and Medicaid. This is expected to increase its appeal among patients seeking treatment for DVT.Medicare and Medicaid reimbursement is crucial for a company like Therma Bright because it opens the door to a vast and stable market of insured patients, ensuring consistent demand for their products. Securing reimbursement from these programs not only validates the effectiveness and necessity of their devices but also simplifies the purchasing process for patients and healthcare providers. For investors, this is a significant milestone as it enhances the company’s revenue potential and reduces financial risk, making Therma Bright a more attractive and reliable investment opportunity.As per the recent announcement, patients will have the option to purchase a pair of Venowave devices outright with a capped reimbursement of $1,199. Alternatively, they can opt for a rental plan, with monthly reimbursement capped at $78.05, totaling $819.55 over 13 months. Ownership of the device will transfer to the patient after the 13th rental payment.Strategic Distribution Partnership SecuredShortly after receiving its new designation, Therma Bright announced a partnership with a major distributor to launch an initial sales program. This initiative aims to assess Medicare and Medicaid reimbursement timelines and billing procedures. If successful, the distributor has agreed to purchase the remaining Venowave VW5 inventory, valued at $2.38 million.While the distributor's identity has not been disclosed, it is expected that further details will emerge as the program progresses. This partnership marks a crucial step towards establishing the VW5 as a preferred DVT treatment, particularly for patients covered by Medicare and Medicaid. Therma Bright's CEO, Rob Fia, anticipates a "significant increase" in monthly orders as a result.Beyond DVT: Expanding the Venowave VW5's ApplicationsWhile the Venowave VW5 is already gaining attention for its role in DVT treatment, its potential applications extend far beyond. The device is capable of addressing a wide range of conditions, significantly broadening Therma Bright's total addressable market.In addition to DVT, the VW5 can be used for:<ol><li>Managing symptoms of post-thrombotic syndrome (PTS)</li><li>Preventing primary thrombosis</li><li>Treating lymphedema</li><li>Reducing post-operative pain and swelling</li><li>Alleviating leg swelling caused by vascular insufficiency</li><li>Treating varicose veins</li><li>Managing chronic venous insufficiency</li><li>Enhancing blood circulation</li><li>Addressing intermittent claudication</li></ol>All of these ailments represent blue sky for Therma Bright as each one of these very common medical issues, as they potentially become approved, would unlock a whole new category of customer for the company.&nbsp;Therma Bright's Diverse, Late-Stage Product Pipeline&nbsp;Therma Bright's diverse product portfolio is a key driver of its investor appeal, with its investment in Inretio at the forefront.&nbsp;Inretio is revolutionizing ischemic stroke treatment with its Preva® clot-retrieval device, which has recently completed its<a href="https://finance.yahoo.com/news/therma-bright-major-milestone-portfolio-100000110.html"> third successful human trial</a>. This groundbreaking technology represents a significant leap in thrombectomy procedures, offering unmatched precision in restoring blood flow for stroke patients, even when traditional treatments like tPA fail.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_28_PM_5b99c7f619.png" alt="Screenshot 2024-09-10 at 5.15.28 PM.png">The Preva® device's patented protective basket design reduces the risk of embolization and minimizes the need for repeated maneuvers, positioning it as a potential game-changer in the global market for advanced clot removal solutions. As Inretio progresses towards FDA 510K designation, the success of the Preva® device underscores the strategic value of Therma Bright's investment in cutting-edge medical technologies.With the global coronary stents market expected to reach $4.8 billion by 2029, the continued development of this device could greatly enhance Therma Bright's portfolio.The $16 Billion COPD MarketTherma Bright is making significant strides with its investment in InStatin, a company developing innovative inhaled statin therapies for respiratory diseases like asthma and Chronic Obstructive Pulmonary Disease (COPD). Unlike traditional statin therapies that are administered orally, InStatin’s novel delivery system targets the airways and lungs directly, potentially offering a more effective treatment at lower dosages. This cutting-edge approach could revolutionize the management of these respiratory conditions, which collectively affect over 600 million people globally.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_34_PM_afe9034042.png" alt="Screenshot 2024-09-10 at 5.15.34 PM.png">The global market for asthma and COPD treatments is substantial, with an estimated value exceeding $16 billion annually. This presents a significant growth opportunity for Therma Bright as InStatin progresses through pre-clinical stages. The unique benefits of inhaled statins—such as reduced tissue thinning and longer-lasting therapeutic effects compared to steroids—position this technology as a promising alternative in a market that has seen little innovation over the past 50 years.With a 17% equity stake in InStatin and a 60% stake in Invixa, Therma Bright is well-positioned to capitalize on the success of these therapies.Turn Your Head and CoughTherma Bright has also played a pivotal role in developing the Digital Cough Test in collaboration with AI4LYF. This innovative app uses artificial intelligence to monitor various respiratory diseases through cough analysis, further diversifying Therma Bright’s product offerings.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_39_PM_68fe2a4028.png" alt="Screenshot 2024-09-10 at 5.15.39 PM.png">Bringing it all TogetherTherma Bright's strategic focus on both medical devices and drug therapies places the company in a unique position within the healthcare sector. The company’s flagship products—ranging from the Venowave VW5 for DVT prevention to the Preva® clot-retrieval device and inhaled statin therapies—target significant, multi-billion-dollar markets. Combined, the market opportunities across these indications surpass $22 billion globally, highlighting the substantial revenue potential for Therma Bright which pales in comparison to their tiny market value of just USD $21 Million.What sets Therma Bright apart is its emphasis on medical devices, which typically face shorter, less expensive, and less risky development timelines compared to pharmaceutical drugs. The company's advancements with the Venowave VW5 and Preva® device, both of which are already far along in the regulatory process, partially de-risk their pipeline. This progress contrasts with the longer, more expensive, and more uncertain path often associated with drug development.&nbsp;By focusing on innovative medical devices that address large and unmet medical needs, Therma Bright is poised to potentially capture significant market share, offering a compelling growth story for investors as it continues to push the boundaries of healthcare innovation.

Therma Bright (TBRIF) Stock Skyrockets After Medicare and Medicaid Milestone, Enters Multi-Billion-Dollar Market

Therma Bright’s Venowave VW5 achieves a Medicare code, boosting its market reach in DVT treatment. With new partnerships and a diverse product pipeline, the company is set for significant growth.

Therma Bright Gains Medicare Milestone, Expands into $1.5B Market

public companies

Therma Bright’s stock surges as its Venowave VW5 device secures a crucial Medicare and Medicaid designation, entering the $1.5B DVT market. With a strategic distribution partnership, Therma Bright is poised for rapid growth in medical devices and therapies.


Click to follow <a href="https://stocktwits.com/symbol/TBRIF">Therma Bright, Inc. </a>(TSXV: THRM) (<a href="https://stocktwits.com/symbol/TBRIF">OTCQB: TBRIF</a>) (FSE: JNX)A burgeoning name in the medical device industry, has achieved a significant breakthrough for its flagship product, the Venowave VW5. This circulation-enhancing device recently secured a crucial designation from the Centers for Medicare and Medicaid Services (CMS), positioning it for success within the expansive Medicare and Medicaid frameworks.The Venowave VW5 has been awarded a permanent Healthcare Common Procedure Coding System (HCPCS) code, a pivotal development that could propel Therma Bright into the forefront of the deep vein thrombosis (DVT) treatment market. Industry estimates project this market to grow to $1.5 billion by 2032, offering substantial growth prospects for Therma Bright, which currently holds a modest market cap of USD $21 million.Introducing Therma Bright: Innovating Blood Clot Prevention, and BeyondTherma Bright, Inc., the innovative force behind the Venowave VW5, specializes in cutting-edge diagnostic and medical device technologies. While the company boasts a diverse portfolio, the Venowave VW5 is currently generating the most investor enthusiasm.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_14_31_PM_5254def16f.png" alt="Screenshot 2024-09-10 at 5.14.31 PM.png">The Venowave VW5 is a device designed to be worn on the calf, where it generates wave-like motions to massage the leg and promote blood circulation. This function is critical in pushing blood back to the heart, helping to prevent blood clotting, particularly in cases of DVT—a condition that affects approximately 900,000 Americans annually, according to the CDC. Unlike traditional compression socks, which can cause discomfort and skin issues, the VW5 offers a more comfortable and effective alternative for DVT patients.Venowave VW5 Achieves Key Medicare &amp; Medicaid DesignationThe Venowave VW5 is the first device of its kind to be classified as Durable Medical Equipment (DME) with a new HCPCS Level II code. This designation enhances the device's credibility as a treatment option and streamlines billing and reimbursement processes through Medicare and Medicaid. This is expected to increase its appeal among patients seeking treatment for DVT.Medicare and Medicaid reimbursement is crucial for a company like Therma Bright because it opens the door to a vast and stable market of insured patients, ensuring consistent demand for their products. Securing reimbursement from these programs not only validates the effectiveness and necessity of their devices but also simplifies the purchasing process for patients and healthcare providers. For investors, this is a significant milestone as it enhances the company’s revenue potential and reduces financial risk, making Therma Bright a more attractive and reliable investment opportunity.As per the recent announcement, patients will have the option to purchase a pair of Venowave devices outright with a capped reimbursement of $1,199. Alternatively, they can opt for a rental plan, with monthly reimbursement capped at $78.05, totaling $819.55 over 13 months. Ownership of the device will transfer to the patient after the 13th rental payment.Strategic Distribution Partnership SecuredShortly after receiving its new designation, Therma Bright announced a partnership with a major distributor to launch an initial sales program. This initiative aims to assess Medicare and Medicaid reimbursement timelines and billing procedures. If successful, the distributor has agreed to purchase the remaining Venowave VW5 inventory, valued at $2.38 million.While the distributor's identity has not been disclosed, it is expected that further details will emerge as the program progresses. This partnership marks a crucial step towards establishing the VW5 as a preferred DVT treatment, particularly for patients covered by Medicare and Medicaid. Therma Bright's CEO, Rob Fia, anticipates a "significant increase" in monthly orders as a result.Beyond DVT: Expanding the Venowave VW5's ApplicationsWhile the Venowave VW5 is already gaining attention for its role in DVT treatment, its potential applications extend far beyond. The device is capable of addressing a wide range of conditions, significantly broadening Therma Bright's total addressable market.In addition to DVT, the VW5 can be used for:- Managing symptoms of post-thrombotic syndrome (PTS)- Preventing primary thrombosis- Treating lymphedema- Reducing post-operative pain and swelling- Alleviating leg swelling caused by vascular insufficiency- Treating varicose veins- Managing chronic venous insufficiency- Enhancing blood circulation- Addressing intermittent claudication&nbsp;All of these ailments represent blue sky for Therma Bright as each one of these very common medical issues, as they potentially become approved, would unlock a whole new category of customer for the company.&nbsp;Therma Bright's Diverse, Late-Stage Product Pipeline&nbsp;Therma Bright's diverse product portfolio is a key driver of its investor appeal, with its investment in Inretio at the forefront.&nbsp;Inretio is revolutionizing ischemic stroke treatment with its Preva® clot-retrieval device, which has recently completed its<a href="https://finance.yahoo.com/news/therma-bright-major-milestone-portfolio-100000110.html"> third successful human trial</a>. This groundbreaking technology represents a significant leap in thrombectomy procedures, offering unmatched precision in restoring blood flow for stroke patients, even when traditional treatments like tPA fail.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_28_PM_5b99c7f619.png" alt="Screenshot 2024-09-10 at 5.15.28 PM.png">The Preva® device's patented protective basket design reduces the risk of embolization and minimizes the need for repeated maneuvers, positioning it as a potential game-changer in the global market for advanced clot removal solutions. As Inretio progresses towards FDA 510K designation, the success of the Preva® device underscores the strategic value of Therma Bright's investment in cutting-edge medical technologies.With the global coronary stents market expected to reach $4.8 billion by 2029, the continued development of this device could greatly enhance Therma Bright's portfolio.The $16 Billion COPD MarketTherma Bright is making significant strides with its investment in InStatin, a company developing innovative inhaled statin therapies for respiratory diseases like asthma and Chronic Obstructive Pulmonary Disease (COPD). Unlike traditional statin therapies that are administered orally, InStatin’s novel delivery system targets the airways and lungs directly, potentially offering a more effective treatment at lower dosages. This cutting-edge approach could revolutionize the management of these respiratory conditions, which collectively affect over 600 million people globally.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_34_PM_afe9034042.png" alt="Screenshot 2024-09-10 at 5.15.34 PM.png">The global market for asthma and COPD treatments is substantial, with an estimated value exceeding $16 billion annually. This presents a significant growth opportunity for Therma Bright as InStatin progresses through pre-clinical stages. The unique benefits of inhaled statins—such as reduced tissue thinning and longer-lasting therapeutic effects compared to steroids—position this technology as a promising alternative in a market that has seen little innovation over the past 50 years.With a 17% equity stake in InStatin and a 60% stake in Invixa, Therma Bright is well-positioned to capitalize on the success of these therapies.Turn Your Head and CoughTherma Bright has also played a pivotal role in developing the Digital Cough Test in collaboration with AI4LYF. This innovative app uses artificial intelligence to monitor various respiratory diseases through cough analysis, further diversifying Therma Bright’s product offerings.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_39_PM_68fe2a4028.png" alt="Screenshot 2024-09-10 at 5.15.39 PM.png">Bringing it all TogetherTherma Bright's strategic focus on both medical devices and drug therapies places the company in a unique position within the healthcare sector. The company’s flagship products—ranging from the Venowave VW5 for DVT prevention to the Preva® clot-retrieval device and inhaled statin therapies—target significant, multi-billion-dollar markets. Combined, the market opportunities across these indications surpass $22 billion globally, highlighting the substantial revenue potential for Therma Bright which pales in comparison to their tiny market value of just USD $21 Million.What sets Therma Bright apart is its emphasis on medical devices, which typically face shorter, less expensive, and less risky development timelines compared to pharmaceutical drugs. The company's advancements with the Venowave VW5 and Preva® device, both of which are already far along in the regulatory process, partially de-risk their pipeline. This progress contrasts with the longer, more expensive, and more uncertain path often associated with drug development.&nbsp;By focusing on innovative medical devices that address large and unmet medical needs, Therma Bright is poised to potentially capture significant market share, offering a compelling growth story for investors as it continues to push the boundaries of healthcare innovation.

<h1>Tiny Healthcare Stock With $35 Million Market Cap Becomes Major Player Overnight in Rapidly Growing $1 Billion Market</h1><h2>Therma Bright (THRM) secures permanent Medicare and Medicaid reimbursement codes for Venowave VW5, making it the only product with reimbursement codes in deep vein thrombosis (DVT) market, expected to grow in value to US $1.55 billion by 2032.</h2>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/therma-bright">Therma Bright (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX)</a>, a leader in proprietary diagnostic and medical device technology, is making significant strides in addressing critical health challenges with its innovative solutions. The company’s&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.newsfilecorp.com/release/220400/Therma-Brights-Venowave-VW5-Secures-Permanent-HCPCS-Code-E0683-from-U.S.-DHHSs-Centers-for-Medicare-Medicaid-Services?k=therma%20bright">latest achievement</a>, the permanent Healthcare Common Procedure Coding System (HCPCS) code E0683 for its Venowave VW5 device, marks a crucial milestone in enhancing patient care and expanding market reach.<h3>Venowave VW5: A Revolutionary Approach to Circulatory Health</h3>The&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.thermabright.com/venowave/">Venowave VW5</a> is a first-of-its-kind piece of Durable Medical Equipment designed to treat and prevent deep vein thrombosis (DVT) and other circulatory issues by utilizing a series of compact, battery-operated peristaltic pumps that generate a wave-form motion.Worn below the knee and strapped firmly to the calf, the Venowave device provides compression to the calf and creates an increased upward volumetric displacement of venous and lymph fluid, resulting in improved vascular and lymphatic flow in the lower limbs.The device, now recognized by the U.S. Department of Health &amp; Human Services’ Centers for Medicare and Medicaid Services (CMS) with its own HCPCS code, offers patients a much-needed alternative to traditional treatments like compression socks. Unlike compression socks, which can cause discomfort and skin issues, the Venowave VW5 uses its wave-form motion to gently massage the calf, improving blood circulation without the associated drawbacks.Rob Fia, CEO of Therma Bright, commented on the milestone announcement, stating:<blockquote>“We’re pleased that the Centers for Medicare and Medicaid has approved our permanent code request, as well as the reimbursement pricing and the new HCPCS Level II designation for our Venowave VW5 device. As shared in several of our recent press announcements, the CDC estimates that over 900,000 U.S. citizens suffer from deep vein thrombosis (DVT) and MarketDigit’s research projected this disease will ‘reach USD 1.5 Billion by 2032’ on a global market value perspective. And DVT is only one medical condition area out of ten circulatory issues that the permanent code will cover, which is very exciting.”</blockquote>The reimbursable codes are not only a great opportunity for Therma Bright but also for the company’s customers, reseller partners and shareholders.The Medicare and Medicaid codes for the Venowave VW5 cover the following ten indications:– Prevention of deep vein thrombosis (DVT) – Management of the symptoms of post-thrombotic syndrome (PTS) – Prevention of primary thrombosis – Treatment of lymphedema – Diminishing post-operative pain and swelling – Treatment of leg swelling due to vascular insufficiency – Treatment of varicose veins – Treatment of chronic venous insufficiency – Enhancing blood circulation – Treatment of intermittent claudicationPer this morning’s Therma Bright&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.newsfilecorp.com/release/220400/Therma-Brights-Venowave-VW5-Secures-Permanent-HCPCS-Code-E0683-from-U.S.-DHHSs-Centers-for-Medicare-Medicaid-Services?k=therma%20bright">press release</a>, the Venowave VW5 will have a complete patient buyout option for a pair of Venowave devices with a capped reimbursement of $1,199.The Venowave VW5 can also be rented with a capped rental fee reimbursement of $78.05 per month. The total capped rental reimbursement payment for 13 months of continuous use is $819.55, and following the 13th rental payment, the patient will become the owner of the Venowave VW5.The device’s impact is underscored by the growing need for effective DVT treatments. The global market for DVT prevention is&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/en/news-release/2024/01/29/2819535/28124/en/Deep-Vein-Thrombosis-Market-Projected-to-Ascend-to-1-26-billion-by-2028-A-Fresh-Global-Market-Report-Unveiled.html">projected to grow</a> steadily at a CAGR of 4.1% and reach US $1.26 billion by 2028 and US $1.55 billion by 2032, driven by an aging population and the increasing prevalence of lifestyle diseases like obesity. With over 900,000 Americans affected by DVT annually, the Venowave VW5 is poised to play a critical role in managing and preventing this life-threatening condition.Highlighting the significance of the development, Fia added:<blockquote>“This innovative device for addressing DVT and these other blood circulation issues is the first-of-its-kind to receive the permanent HCPCS Level II code, and we look to provide an initial sales update on our solution in the coming week. One key competitive product in the marketplace is the compression sock, which applies controlled and constant pressure on the leg to improve blood flow in the veins. Unfortunately, users of the compression socks can experience a variety of challenges, including difficulty in putting the sock on, discomfort from constant pressure, minor bruising, skin ulcers, dry skin, redness, and itching. In contrast, the Venowave VW5 simply straps on and massages the leg, applying appropriate pressure in a comfortable and soothing manner to circulate blood through the veins.”</blockquote><h3>Expanding the Portfolio: AI-Powered Solutions and Strategic Investments</h3><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.thermabright.com/">Therma Bright</a>‘s commitment to innovation extends beyond the Venowave VW5. The company is also at the forefront of integrating artificial intelligence (AI) into healthcare, as demonstrated by its Digital Cough Technology (DCT). Developed in partnership with&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.thermabright.com/ai4lyf/">AI4LYF</a>, this AI-powered platform is currently&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.newsfilecorp.com/release/220173/Therma-Brights-AIPowered-Digital-Cough-Technology-Being-Considered-as-Partner-Technology-in-New-Chronic-Cough-Drug-Clinical-Trial">under consideration</a> for a U.S. clinical trial involving a new chronic cough drug. The DCT platform enables healthcare providers and epidemiologists to make more accurate and informed decisions by analyzing cough sounds, thereby improving the diagnosis and management of respiratory conditions.Fia explained:<blockquote>“Our DCT solution and data collection platform is ideally positioned for clinical studies like this one. It allows health practitioners to quickly address a patient’s respiratory issues, ultimately leading to better health outcomes.”</blockquote>Therma Bright’s strategic investments further solidify its position in the medical device industry. The company’s portfolio includes a stake in Inretio, which is revolutionizing ischemic stroke treatment with its innovative clot-retrieving device, PREVATM. This technology has shown promising results in early trials, achieving an 80% success rate compared to the 50% effectiveness of existing devices. Additionally, Therma Bright is developing inhaled statin therapies for asthma and COPD, offering a new approach to treating these widespread respiratory conditions.<h3>The Road Ahead: A Focus on Patient-Centered Innovation</h3>Therma Bright’s focus on patient-centred innovation is evident in its approach to product development and market expansion. The company’s Venowave VW5 not only provides a new standard in DVT treatment but also sets the stage for further advancements in circulatory and respiratory health.As the healthcare landscape continues to evolve, Therma Bright is well-positioned to lead the way with its cutting-edge technologies. With the Venowave VW5 already making waves in the market and its AI-powered DCT platform on the brink of clinical integration, the company is poised to make a lasting impact on the health and well-being of millions.<h3>Therma Bright (TSXV: THRM) Stock Price Action</h3>Shares of Therma Bright stock are in the midst of an epic breakout, with THRM stock up as much as&nbsp;350% since July 31, 2024, and as much as&nbsp;800% since May 31, 2024.Therma Bright stock last traded at $0.085. YTD, THRM stock is up&nbsp;183.33%.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_20_at_7_52_22_PM_ae153f1a0d.png" alt="Screenshot 2024-08-20 at 7.52.22 PM.png" width="1436" height="864">Therma Bright, (TSXV: THRM), six-month interactive stock chart. (Source: Barchart)<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.barchart.com/stocks/quotes/THRM.VN/interactive-chart">View Therma Bright Stock Chart on Barchart</a>Read Next:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/biotech/tempest-therapeutics-tpst-stock-jumps-83-on-fda-phase-3-trial-news/">Tempest Therapeutics (TPST) Stock Jumps 83% on FDA Phase 3 Trial News</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at&nbsp;Invest@WealthyVC.comTherma Bright Inc. (CSE: PAID) is a paid client of Wealthy VC. This report/release/profile is a commercial advertisement and is for general information purposes only.&nbsp;&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

Tiny Healthcare Stock With $35 Million Market Cap Becomes Major Player Overnight in Rapidly Growing $1 Billion Market

Therma Bright secures Medicare codes for its Venowave VW5, boosting its market presence in the $1.5B DVT market and driving an 800% stock surge since May 2024.

Therma Bright Gains Medicare Code for Venowave, Stock Soars

Equity

Therma Bright (TSXV: THRM) secures permanent Medicare and Medicaid reimbursement codes for its Venowave VW5 device, making it the only DVT treatment with such codes. This innovation has driven significant stock gains, with shares rising over 800% since May 2024.

Therma Bright, Inc. engages in developing and marketing skin care medical device products. Its products include Therapik, which is used to relieve the pain, itch and inflammation of stings and bites from different species of insects and InterceptCS, which is a device to prevent cold sore outbreaks. The company was founded in 2001 and is headquartered in Toronto, Canada.

Therma Bright Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$0.0512
Prev Close	$0.0643
Open	$0.0512
Dividend Yield	0.00%
50-Day Moving Average	$0.0547
Beta	0.56
Avg. Volume	2,756.14
PE Ratio	-1.07

52-Week High	$0.344
52-Week Low	$0.0338
Market Capitalization	$4.26M
EPS (Annual)	-$0.0453
Price to Book	3.52
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

TBRIF
Therma Bright Inc

Feed

News

Sentiment

Fundamentals

Info

Latest TBRIF News

TBRIFTherma Bright Inc